<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/396A4389-FD2B-4EDD-A3A5-3321E285E5AB"><gtr:id>396A4389-FD2B-4EDD-A3A5-3321E285E5AB</gtr:id><gtr:name>University of Indonesia</gtr:name><gtr:address><gtr:line1>P.O. BOX 3852</gtr:line1><gtr:line4>Jakarta</gtr:line4><gtr:line5>10038</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Indonesia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E68BE577-6C17-48CE-B65C-24C477BB8AE9"><gtr:id>E68BE577-6C17-48CE-B65C-24C477BB8AE9</gtr:id><gtr:name>Yeshiva University</gtr:name><gtr:address><gtr:line1>500 West 185th Street</gtr:line1><gtr:postCode>10033</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/671BE36F-3E43-4202-A9FB-CDB7A5629797"><gtr:id>671BE36F-3E43-4202-A9FB-CDB7A5629797</gtr:id><gtr:name>Cho Ray Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E0226576-B02A-480A-B953-F870F7FDA94B"><gtr:id>E0226576-B02A-480A-B953-F870F7FDA94B</gtr:id><gtr:name>Hospital for Tropical Diseases HCM</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/303E2392-4064-48A4-99F4-4ADB9D75C377"><gtr:id>303E2392-4064-48A4-99F4-4ADB9D75C377</gtr:id><gtr:name>St George's Hospital</gtr:name><gtr:address><gtr:line1>Blackshaw Road</gtr:line1><gtr:line2>Tooting</gtr:line2><gtr:postCode>SW17 0QT</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/850FC189-F1EA-472B-8E60-0F1DBA42212D"><gtr:id>850FC189-F1EA-472B-8E60-0F1DBA42212D</gtr:id><gtr:name>Wellcome Trust-Mahosot Hospital-Oxford University Tropical Medicine Research Collaboration</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5569A12-0A1B-4474-B608-84BB0C44B3A7"><gtr:id>F5569A12-0A1B-4474-B608-84BB0C44B3A7</gtr:id><gtr:name>University of Minnesota</gtr:name><gtr:address><gtr:line1>127 Vincent Hall</gtr:line1><gtr:line2>206 Church St. S.E</gtr:line2><gtr:line4>Minneapolis</gtr:line4><gtr:line5>MN 55455</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Tropical Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/396A4389-FD2B-4EDD-A3A5-3321E285E5AB"><gtr:id>396A4389-FD2B-4EDD-A3A5-3321E285E5AB</gtr:id><gtr:name>University of Indonesia</gtr:name><gtr:address><gtr:line1>P.O. BOX 3852</gtr:line1><gtr:line4>Jakarta</gtr:line4><gtr:line5>10038</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Indonesia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E68BE577-6C17-48CE-B65C-24C477BB8AE9"><gtr:id>E68BE577-6C17-48CE-B65C-24C477BB8AE9</gtr:id><gtr:name>Yeshiva University</gtr:name><gtr:address><gtr:line1>500 West 185th Street</gtr:line1><gtr:postCode>10033</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/671BE36F-3E43-4202-A9FB-CDB7A5629797"><gtr:id>671BE36F-3E43-4202-A9FB-CDB7A5629797</gtr:id><gtr:name>Cho Ray Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E0226576-B02A-480A-B953-F870F7FDA94B"><gtr:id>E0226576-B02A-480A-B953-F870F7FDA94B</gtr:id><gtr:name>Hospital for Tropical Diseases HCM</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/303E2392-4064-48A4-99F4-4ADB9D75C377"><gtr:id>303E2392-4064-48A4-99F4-4ADB9D75C377</gtr:id><gtr:name>St George's Hospital</gtr:name><gtr:address><gtr:line1>Blackshaw Road</gtr:line1><gtr:line2>Tooting</gtr:line2><gtr:postCode>SW17 0QT</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/850FC189-F1EA-472B-8E60-0F1DBA42212D"><gtr:id>850FC189-F1EA-472B-8E60-0F1DBA42212D</gtr:id><gtr:name>Wellcome Trust-Mahosot Hospital-Oxford University Tropical Medicine Research Collaboration</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5569A12-0A1B-4474-B608-84BB0C44B3A7"><gtr:id>F5569A12-0A1B-4474-B608-84BB0C44B3A7</gtr:id><gtr:name>University of Minnesota</gtr:name><gtr:address><gtr:line1>127 Vincent Hall</gtr:line1><gtr:line2>206 Church St. S.E</gtr:line2><gtr:line4>Minneapolis</gtr:line4><gtr:line5>MN 55455</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/42CE62AA-63C7-447E-8692-AE40469EF4A2"><gtr:id>42CE62AA-63C7-447E-8692-AE40469EF4A2</gtr:id><gtr:firstName>Anatoli</gtr:firstName><gtr:surname>Kamali</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9024380E-ED08-4727-8AAD-E2864A7D31CF"><gtr:id>9024380E-ED08-4727-8AAD-E2864A7D31CF</gtr:id><gtr:firstName>Cuong</gtr:firstName><gtr:otherNames>Duy</gtr:otherNames><gtr:surname>Do</gtr:surname><gtr:orcidId>0000-0001-9940-2306</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A9FE7ED9-3277-4CBC-A0B7-F01E3EBAD0BF"><gtr:id>A9FE7ED9-3277-4CBC-A0B7-F01E3EBAD0BF</gtr:id><gtr:firstName>Wirongrong</gtr:firstName><gtr:surname>Chierakul</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C910191D-7AC8-4F36-8F84-9A1D352F490C"><gtr:id>C910191D-7AC8-4F36-8F84-9A1D352F490C</gtr:id><gtr:firstName>Camilla</gtr:firstName><gtr:surname>Rothe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C02A0294-8267-4C18-AA4D-6186D308971D"><gtr:id>C02A0294-8267-4C18-AA4D-6186D308971D</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Lalloo</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/45E2AD99-3968-48C8-BBBD-388F04A66ABA"><gtr:id>45E2AD99-3968-48C8-BBBD-388F04A66ABA</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>Simon</gtr:otherNames><gtr:surname>Heyderman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E59036C9-53A6-42FA-BEF7-CAD039AC984F"><gtr:id>E59036C9-53A6-42FA-BEF7-CAD039AC984F</gtr:id><gtr:firstName>Mayfong</gtr:firstName><gtr:surname>Mayxay</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4078502E-4611-49D3-8E8A-05B4F529EA45"><gtr:id>4078502E-4611-49D3-8E8A-05B4F529EA45</gtr:id><gtr:firstName>Hanh</gtr:firstName><gtr:surname>Doan Thi Hong</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B6B9BBF4-BE38-40E2-AE0B-AAEE2E5B04EA"><gtr:id>B6B9BBF4-BE38-40E2-AE0B-AAEE2E5B04EA</gtr:id><gtr:firstName>Marcel</gtr:firstName><gtr:surname>Wolbers</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/84AD4D4A-EFB9-4696-A8FF-5712291BC58E"><gtr:id>84AD4D4A-EFB9-4696-A8FF-5712291BC58E</gtr:id><gtr:firstName>Chau</gtr:firstName><gtr:surname>Tran Thi Hong</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/38B289EF-CABF-45B0-9B8E-80A7270D197C"><gtr:id>38B289EF-CABF-45B0-9B8E-80A7270D197C</gtr:id><gtr:firstName>Halima</gtr:firstName><gtr:surname>Dawood</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/08A7725D-D312-4AA2-BB7F-8287EF8A1589"><gtr:id>08A7725D-D312-4AA2-BB7F-8287EF8A1589</gtr:id><gtr:firstName>Kinh</gtr:firstName><gtr:surname>Nguyen Van</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/62FA883E-3223-435B-A311-F9B9133DE739"><gtr:id>62FA883E-3223-435B-A311-F9B9133DE739</gtr:id><gtr:firstName>Darma</gtr:firstName><gtr:surname>Imran</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/01478514-975B-4C23-A8CC-65E12F8AE90D"><gtr:id>01478514-975B-4C23-A8CC-65E12F8AE90D</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:surname>Day</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100684"><gtr:id>3EF699FB-6BE5-4737-B030-3CFFC9A7823B</gtr:id><gtr:title>A clinical trial of dexamethasone to reduce mortality in cryptococcal meningitis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100684</gtr:grantReference><gtr:abstractText>Cryptococcal meningitis is a brain infection due to a yeast called Cryptococcus neoformans. It is important because it is a major cause of death in people infected with HIV. There are over 600 000 deaths each year, and most of these occur in poorer countries in Africa and Asia. Even if patients receive treatment with antifungal drugs, the death rate remains high - about 55% of people with disease in Asia and 70% in Africa will die within 3 months of diagnosis. A combination of antifungal drugs is given to kill the yeast, but researchers have been unable to improve on the antifungal treatment combination that has been recommended for the past 10 years. This is despite extensive research. We believe that new approaches are needed to try and improve outcome in this disease. The features of infectious diseases are the result of not only the infectious agent, but also the way our bodies respond to them. When our bodies? immune systems fight infection, this causes inflammation which can sometimes make disease worse. When people have cryptococcal meningitis, there is inflammation and raised pressure in the brain. The inflammation can result in parts of the brain dying (a stroke). The raised pressure leads to the brain getting squeezed (compressed) against the inside of the skull. This can impair the blood supply and can directly damage the brain tissue itself. These processes can lead to death. Steroids are drugs that can reduce inflammation, and are frequently used to lower raised pressure in brain diseases. They have been found to be useful in other forms of meningitis, such as acute bacterial meningitis and tuberculous meningitis. These diseases share some features with cryptococcal meningitis. We want to test whether giving dexamethasone, a steroid, alongside antifungal therapy, can reduce the death rate in people with cryptococcal meningitis. Dexamethasone is cheap, safe, and widely available, and if successful is a treatment that would be affordable and practical for the majority of patients around the world with this disease. We want to do this study in Africa and Asia, because this is where most people with cryptococcal meningitis live.</gtr:abstractText><gtr:technicalSummary>Cryptococcal meningitis is the leading cause of death in HIV patients in Asia and Africa with death rates between 55 and 70%. There are an estimated 625 000 deaths each year, most occurring in poorer countries and within 3 months of diagnosis. There has been no major advance in treatment since 1997 - no combination of antifungal drugs with greater sterilizing power than amphotericin and flucytosine has since been identified. In order to make a significant impact on mortality, alternative approaches need to be trialled. Adjuvant therapies are relatively untested in cryptococcal meningitis. Raised intracranial pressure, vasculitis with infarction and cerebral oedema are all complications of cryptococcal meningitis and are believed to contribute towards its high mortality. These pathologies are potentially modifiable with dexamethasone. Dexamethasone is a corticosteroid which is frequently used to treat intracranial pathology including vasculitides, raised pressure, and cerebral oedema. It is of proven benefit in reducing the death rate of tuberculous meningitis, a chronic meningitis that has some pathophysiological similarities to cryptococcal meningitis. Moreover, it has an excellent safety profile, is cheap and practicable. In addition, animal studies show that dexamethasone does not impair the action of antifungal drugs. 
Therefore, we propose a multicentre double blind randomised controlled trial of dexamethasone in HIV infected patients with cryptococcal meningitis. The study will be based in countries in Africa (Uganda, South Africa, Malawi) and Southeast Asia (Thailand, Laos, Vietnam, Indonesia) where this disease is a significant health burden, and in centres with track records of successful completion of large clinical trials and the subsequent translation of findings into national and international policy. The multi-centre nature of the trial, recruiting in African and Asian countries, ensures that the results of the trial will have generalizability and impact. The primary endpoint will be survival until 10 weeks after randomization. The study will have 80% power to detect a reduction in the death rate of 30% (Hazard Ratio 0.7), and will require 880 patients (allowing for 10% loss to follow up). The study will also have 80% power to detect a 40% reduction in death rate in each continent. Patients will receive optimised antifungal therapy and be randomised to receive dexamethasone or identical placebo. Secondary endpoints include disability, survival to 6 months, adverse event rates, opportunistic infection rates and the rate of fungal clearance.</gtr:technicalSummary><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>4217874</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Indonesia</gtr:collaboratingOrganisation><gtr:country>Indonesia, Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>CryptoDex Study</gtr:description><gtr:id>54B1455E-EC8D-4932-A26B-9A112EAC8988</gtr:id><gtr:impact>Study is in early stages but ethical and other pemissions sort and expect to begin study recruitment end of 2012</gtr:impact><gtr:outcomeId>Cw8sgEZSSbU-4</gtr:outcomeId><gtr:partnerContribution>Review of the study protocol and grant application, ethcial submissions and permissions, patient recruitment, day to day runnning of the trial</gtr:partnerContribution><gtr:piContribution>I am the PI, designed the study, funding application, SOPs, CRFs, assembled the study team.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PK/PD of antifungals</gtr:description><gtr:id>A43A9607-736F-4292-BFDF-02EE731F6399</gtr:id><gtr:impact>On-going</gtr:impact><gtr:outcomeId>544dd74fa6c4a5.57672732-1</gtr:outcomeId><gtr:partnerContribution>William Hope and UNiversity of liverpool provide measurement of drug levels and expertise in analysis of results and data modelling.</gtr:partnerContribution><gtr:piContribution>Collaboration to understand the PK and PD of antifungal drugs in cryptococcal meningitis. We arrange and run the clinical studies, and obtain the clinical specimens and measure the pharmacodynamic outcome.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Minnesota</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Fungal counts as a surrogate marker in cryptococcal disease</gtr:description><gtr:id>5C9D8D5B-683E-4E96-B46A-945F18C2857E</gtr:id><gtr:impact>On-going</gtr:impact><gtr:outcomeId>544dd215630615.84761797-2</gtr:outcomeId><gtr:partnerContribution>Provide data on fungal count and outcome form the patients in their studies.</gtr:partnerContribution><gtr:piContribution>We drive this collaboration between the main clinical trial groups in cryptococcal meningitis collating the data and perfoming the modelling analyses to determine whether rates of decline of yeast count in cerebrospinal fluid can serve as a surrogate marker of antifungal treatment in cryptococcal disease.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Medical Mycology</gtr:department><gtr:description>Pathogenicity of C. neoformans</gtr:description><gtr:id>F2BF57E6-64C4-4233-98B1-69DD071BB1EC</gtr:id><gtr:impact>None as yet, but a PhD student will visit their lab for 6 months early 2014</gtr:impact><gtr:outcomeId>YZon9wsiJc7-1</gtr:outcomeId><gtr:partnerContribution>DUke will provide animal models and help with next generations equencing technology and data interpretation.</gtr:partnerContribution><gtr:piContribution>In collaboration with Duke university we are investigating the relative pathogenicity of different types of C. neoformans. This work is funded through my Wellcome Trust Intermediate Fellowship.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:department>Medical Research Council (MRC), MRC/UVRI Unit, Uganda</gtr:department><gtr:description>CryptoDex Study</gtr:description><gtr:id>4C7C6BCA-E279-4875-8B27-D0EA55BD8522</gtr:id><gtr:impact>Study is in early stages but ethical and other pemissions sort and expect to begin study recruitment end of 2012</gtr:impact><gtr:outcomeId>Cw8sgEZSSbU-1</gtr:outcomeId><gtr:partnerContribution>Review of the study protocol and grant application, ethcial submissions and permissions, patient recruitment, day to day runnning of the trial</gtr:partnerContribution><gtr:piContribution>I am the PI, designed the study, funding application, SOPs, CRFs, assembled the study team.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Liverpool School of Tropical Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CryptoDex Study</gtr:description><gtr:id>588C381A-30D0-4358-92E6-CBAE6E78504B</gtr:id><gtr:impact>Study is in early stages but ethical and other pemissions sort and expect to begin study recruitment end of 2012</gtr:impact><gtr:outcomeId>Cw8sgEZSSbU-2</gtr:outcomeId><gtr:partnerContribution>Review of the study protocol and grant application, ethcial submissions and permissions, patient recruitment, day to day runnning of the trial</gtr:partnerContribution><gtr:piContribution>I am the PI, designed the study, funding application, SOPs, CRFs, assembled the study team.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:department>Mahidol University-Oxford Tropical Medicine Research Programme</gtr:department><gtr:description>CryptoDex Study</gtr:description><gtr:id>0DCD0C27-8FB1-4A70-A32F-4B4E76D0EA70</gtr:id><gtr:impact>Study is in early stages but ethical and other pemissions sort and expect to begin study recruitment end of 2012</gtr:impact><gtr:outcomeId>Cw8sgEZSSbU-9</gtr:outcomeId><gtr:partnerContribution>Review of the study protocol and grant application, ethcial submissions and permissions, patient recruitment, day to day runnning of the trial</gtr:partnerContribution><gtr:piContribution>I am the PI, designed the study, funding application, SOPs, CRFs, assembled the study team.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Fungal counts as a surrogate marker in cryptococcal disease</gtr:description><gtr:id>EC584F15-1C7F-42CC-B792-1F97735BF505</gtr:id><gtr:impact>On-going</gtr:impact><gtr:outcomeId>544dd215630615.84761797-1</gtr:outcomeId><gtr:partnerContribution>Provide data on fungal count and outcome form the patients in their studies.</gtr:partnerContribution><gtr:piContribution>We drive this collaboration between the main clinical trial groups in cryptococcal meningitis collating the data and perfoming the modelling analyses to determine whether rates of decline of yeast count in cerebrospinal fluid can serve as a surrogate marker of antifungal treatment in cryptococcal disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust</gtr:collaboratingOrganisation><gtr:country>Malawi, Republic of</gtr:country><gtr:department>Malawi-Liverpool Wellcome Trust Clinical Research Programme</gtr:department><gtr:description>CryptoDex Study</gtr:description><gtr:id>3FB72DAA-59B7-4C67-9ADA-10CB1F607F79</gtr:id><gtr:impact>Study is in early stages but ethical and other pemissions sort and expect to begin study recruitment end of 2012</gtr:impact><gtr:outcomeId>Cw8sgEZSSbU-3</gtr:outcomeId><gtr:partnerContribution>Review of the study protocol and grant application, ethcial submissions and permissions, patient recruitment, day to day runnning of the trial</gtr:partnerContribution><gtr:piContribution>I am the PI, designed the study, funding application, SOPs, CRFs, assembled the study team.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cho Ray Hospital</gtr:collaboratingOrganisation><gtr:country>Vietnam, Socialist Republic of</gtr:country><gtr:department>Department of Tropical Medicine</gtr:department><gtr:description>CryptoDex Study</gtr:description><gtr:id>52036B6A-504A-4836-85E3-102DD5A4B6E9</gtr:id><gtr:impact>Study is in early stages but ethical and other pemissions sort and expect to begin study recruitment end of 2012</gtr:impact><gtr:outcomeId>Cw8sgEZSSbU-8</gtr:outcomeId><gtr:partnerContribution>Review of the study protocol and grant application, ethcial submissions and permissions, patient recruitment, day to day runnning of the trial</gtr:partnerContribution><gtr:piContribution>I am the PI, designed the study, funding application, SOPs, CRFs, assembled the study team.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital for Tropical Diseases HCM</gtr:collaboratingOrganisation><gtr:country>Vietnam, Socialist Republic of</gtr:country><gtr:description>CryptoDex Study</gtr:description><gtr:id>D40CA87D-BF84-484A-B927-57946ABEB0C5</gtr:id><gtr:impact>Study is in early stages but ethical and other pemissions sort and expect to begin study recruitment end of 2012</gtr:impact><gtr:outcomeId>Cw8sgEZSSbU-7</gtr:outcomeId><gtr:partnerContribution>Review of the study protocol and grant application, ethcial submissions and permissions, patient recruitment, day to day runnning of the trial</gtr:partnerContribution><gtr:piContribution>I am the PI, designed the study, funding application, SOPs, CRFs, assembled the study team.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:department>Mahidol University-Oxford Tropical Medicine Research Programme</gtr:department><gtr:description>CryptoDex Study</gtr:description><gtr:id>AD63CBD9-BE04-4764-89C5-C3A893CFF80A</gtr:id><gtr:impact>Study is in early stages but ethical and other pemissions sort and expect to begin study recruitment end of 2012</gtr:impact><gtr:outcomeId>Cw8sgEZSSbU-6</gtr:outcomeId><gtr:partnerContribution>Review of the study protocol and grant application, ethcial submissions and permissions, patient recruitment, day to day runnning of the trial</gtr:partnerContribution><gtr:piContribution>I am the PI, designed the study, funding application, SOPs, CRFs, assembled the study team.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Population genetics of C. neoformans</gtr:description><gtr:id>0FC83702-8D6E-4752-B3AD-F1BBC96CC2C3</gtr:id><gtr:impact>On-going work</gtr:impact><gtr:outcomeId>56b0643a27e863.37683069-1</gtr:outcomeId><gtr:partnerContribution>The Sanger Institute will carry out the sequencing work and provide advice and bioinformatic analysis and advice</gtr:partnerContribution><gtr:piContribution>We have amassed a library of 800 strains of Cryptococcus neoformans. These are being sequenced in collbaortion with the Sanger Institute. Data will be analysed by my PhD student</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albert Einstein College of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>B Cell studies in cryptococcal meningitis</gtr:description><gtr:id>F572C17F-B754-4A11-8590-B26F0BF9989A</gtr:id><gtr:impact>None as yet - studies are on-going</gtr:impact><gtr:outcomeId>TVwx7D9eRpL-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators have the laboratory expertise to investigate host susceptibility to cryptococcal disease, which complements our grousp focus on the pathogen itself.</gtr:partnerContribution><gtr:piContribution>We design clinical studies to provide clinical samples in order to further understand the factors that confer increased susceptibility to infection with Cryptococcus neoformans in HIV infected an duninfected patients.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust-Mahosot Hospital-Oxford University Tropical Medicine Research Collaboration</gtr:collaboratingOrganisation><gtr:country>Lao People's Democratic Republic</gtr:country><gtr:description>CryptoDex Study</gtr:description><gtr:id>432F3C22-7DF0-4544-9F39-B918CEA02871</gtr:id><gtr:impact>Study is in early stages but ethical and other pemissions sort and expect to begin study recruitment end of 2012</gtr:impact><gtr:outcomeId>Cw8sgEZSSbU-5</gtr:outcomeId><gtr:partnerContribution>Review of the study protocol and grant application, ethcial submissions and permissions, patient recruitment, day to day runnning of the trial</gtr:partnerContribution><gtr:piContribution>I am the PI, designed the study, funding application, SOPs, CRFs, assembled the study team.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>'Beyond the Hospital' - determine the community experiences and resources that benefit survivors of brain infections in order to develop a discharge pack to aid discharge and recovery in the community</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E77ED778-BCDE-4F3F-B276-CA552C549568</gtr:id><gtr:impact>This is on-going. we are consulting with survivors of neruological infections to understand how they have coped with disability in an environment where there is a paucity of resources to enable folk to cope with diability. we are engagingwith health care workers to understand the perceptions of the difficulties fo such patients. we will develop a resource detailing facilitues, NGOs etc avaialble in teh community to be shread by health care workers with patients on discharge in order ot lead to more successful rehabilittaion and improve communciation between health care workers and patients.

On-going project. we hope to influence discharge planning at govenrment hospitals and patient recovery.</gtr:impact><gtr:outcomeId>544dcfe5dd2a18.68410668</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Ask the scientists' magazine page</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>264FD46F-0F64-444E-AC25-B04F8EA5B73F</gtr:id><gtr:impact>Devised, set up and coordinate the 'Ask the scientist' page in a national Vietnamese childrens magazine. Has a weekly readership of &amp;gt; 50 000. Children send science questions in to us and we publish these alng side answers from a panel of Vietnamese and interational scientists with broad skills and interests that we ahve assembled.

Very popular - hundreds of questions received</gtr:impact><gtr:outcomeId>564eb91b80c758.24677913</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Contributed 2 articles to a local children's magazine on science - venomous snakes and the world of fungi.</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>68528BEF-C351-41FB-A099-8A3599E5E9CE</gtr:id><gtr:impact>The magazine has a circulation of approximatley 50 000 children per week.

Has stimulated children to contact us with questions about science</gtr:impact><gtr:outcomeId>544dcecc217ba1.61995021</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>International Engagement Award</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>7F45CB88-7B04-4EFD-B44A-D77B16417D35</gtr:id><gtr:outcomeId>56b05d6be7de25.71721111</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1420000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Intermediate Clinical Fellowship</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>964D95A3-BB5E-498A-8B2F-119241CEA624</gtr:id><gtr:outcomeId>C4EtpRrzSna</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CryptoDex Trial results references in the HIV InSIte website run by UCSF</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>http://hivinsite.ucsf.edu/InSite?page=md-ward86-cryptococcosis</gtr:guidelineTitle><gtr:id>70E861FB-BB23-420B-B42A-F9AFBB189C69</gtr:id><gtr:impact>Updates the use of corticosteroids in HIV associated cryptococcal meningitis</gtr:impact><gtr:outcomeId>58a045386d52c2.36801696</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://hivinsite.ucsf.edu/InSite?page=md-ward86-cryptococcosis</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CryptoDex trial cited in a review article on management of opportunistic brain infections: Nature Reviews Neurology 12, 662-674 (2016)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>6E4DFBE0-3EBB-4148-A2BA-051BB93040FF</gtr:id><gtr:impact>The results of our trial will influence use of corticosteroids in cryptococcal meningitis and will prevent unnecessary deaths. there are between 300 000 and 600 000 cases of cryptical meningitis per year.</gtr:impact><gtr:outcomeId>58a0433c973301.77016424</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type><gtr:url>http://www.nature.com/nrneurol/journal/v12/n11/abs/nrneurol.2016.149.html</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>In collaboration with Liverpoool University we are defining the pharmacodynamic and kinetice realtionships of amphotericin b and fluconaozle in blood and cerebrospinal fluid uisng novel modelling techniques</gtr:description><gtr:id>80ACCDFD-094E-4419-BC02-55E6E398EBFD</gtr:id><gtr:impact>We hope this study will lead to more rational use of antifungal therapy in cryptococcal menignitis, define the hetrogeneity in treatment respo9nse in a real world situatiion, and so help us to continue to improve outcomes.</gtr:impact><gtr:outcomeId>564eb6b4120434.65619234</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Pharmacokinetics and dynamics of WHO recommended antifungal tehrapy in cryptococcal meningitis in Vietnam and Uganda</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A randomised placebo controlled trial of adjunctive treatment wit dexamethasone in HIV associated cryptococcal meningitis.</gtr:description><gtr:id>03F600F4-097A-454F-B32B-CD9FEDCB9514</gtr:id><gtr:impact>This is an on-going clinical trial that beagn recruiting patients across 6 countries in February 2013. The estimated date for follo-wup completion is 2015/16. This is the first ever RCT of adjunctive treatment in cryptococcal meningitis and will be the largest ever RCT in cryptococcal disease.</gtr:impact><gtr:outcomeId>KbwtR8wbxpb</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>CryptoDex Study</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN59144167</gtr:ukcrnIsctnId><gtr:url>http://www.controlled-trials.com/ISRCTN59144167/</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>We have combined our patient datasets with those from other clinical resarch groups (University of Minnesota, MORU Thailand, St Geaorge's Hospital UK) in order to model the declines in fungal counts in realtion to different antifungal therapies to determine whether these surrogate data can be used to predict clinical outcome from cryptococcal disease.</gtr:description><gtr:id>237CED0F-5674-43EF-B0D4-13EA1F7EA1DA</gtr:id><gtr:impact>We are driving this analysis. We have combined our data with other groups. all grouls can access the data.</gtr:impact><gtr:outcomeId>564eb5ad092b78.09607954</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Early fungicidal activity as a surrogate marker for survival in cryptococcal meningitis</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>67CE04C5-BCF4-4325-A035-204853C016A4</gtr:id><gtr:title>The decline of typhoid and the rise of non-typhoid salmonellae and fungal infections in a changing HIV landscape: bloodstream infection trends over 15 years in southern Vietnam.</gtr:title><gtr:parentPublicationTitle>Transactions of the Royal Society of Tropical Medicine and Hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/598c463aaba8eab10307c43bb1339d04"><gtr:id>598c463aaba8eab10307c43bb1339d04</gtr:id><gtr:otherNames>Nga TV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0035-9203</gtr:issn><gtr:outcomeId>pm_14098_28_22137537</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06998C54-4545-4F8A-853D-1EA22515D92F</gtr:id><gtr:title>Open access Clinical Trials in Cryptococcal Meningitis.</gtr:title><gtr:parentPublicationTitle>Mycoses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a81ba81d77ea4522025519116390463"><gtr:id>4a81ba81d77ea4522025519116390463</gtr:id><gtr:otherNames>JN Day</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>544dc767545a90.76545972</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FDCC845-A60B-4D3F-BE28-C57118411491</gtr:id><gtr:title>Dexamethasone in Cryptococcal Meningitis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c4724e2a5c7d3379ef01fabff0b7f22"><gtr:id>6c4724e2a5c7d3379ef01fabff0b7f22</gtr:id><gtr:otherNames>Beardsley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>58a038ee251681.75338512</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8314FED-C3E4-4C6B-9208-70EF6D7A2687</gtr:id><gtr:title>High prevalence of PI resistance in patients failing second-line ART in Vietnam.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e2fdca735ca5352dcce9ebbfa672877"><gtr:id>1e2fdca735ca5352dcce9ebbfa672877</gtr:id><gtr:otherNames>Thao VP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>564eaf606d40e1.98885539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D568074F-0F42-4455-95F5-CE09BDE61F5A</gtr:id><gtr:title>Combination antifungal therapy for cryptococcal meningitis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f7aa2ed083c8bd45d89b327a099cdfa"><gtr:id>4f7aa2ed083c8bd45d89b327a099cdfa</gtr:id><gtr:otherNames>Day JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_14098_28_23802521</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0F2EF4F-9801-488F-A907-18F2616684D5</gtr:id><gtr:title>Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c4724e2a5c7d3379ef01fabff0b7f22"><gtr:id>6c4724e2a5c7d3379ef01fabff0b7f22</gtr:id><gtr:otherNames>Beardsley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>564eb2b3a46490.73339832</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB37195B-B8FB-4D4C-8412-75C716CDC8AE</gtr:id><gtr:title>Aetiologies of central nervous system infection in Viet Nam: a prospective provincial hospital-based descriptive surveillance study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba18b60534df7f6ede08097c0df47416"><gtr:id>ba18b60534df7f6ede08097c0df47416</gtr:id><gtr:otherNames>Ho Dang Trung N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14098_28_22662232</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>557F046C-2288-4712-A8FA-2EBF3D53A315</gtr:id><gtr:title>Influence of antituberculosis drug resistance and Mycobacterium tuberculosis lineage on outcome in HIV-associated tuberculous meningitis.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e01116bac7f25c23ce9fd65cf9df42"><gtr:id>63e01116bac7f25c23ce9fd65cf9df42</gtr:id><gtr:otherNames>Tho DQ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_14098_28_22470117</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34F769C4-F3ED-41FB-B8CC-1182CDC6977A</gtr:id><gtr:title>Estimating the burden of fungal disease in Vietnam.</gtr:title><gtr:parentPublicationTitle>Mycoses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c4724e2a5c7d3379ef01fabff0b7f22"><gtr:id>6c4724e2a5c7d3379ef01fabff0b7f22</gtr:id><gtr:otherNames>Beardsley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0933-7407</gtr:issn><gtr:outcomeId>564eab07f1a457.60431035</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFAD8FF2-B12D-47E3-9F91-0C52630E0719</gtr:id><gtr:title>CryptoDex: a randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9a462504f3ef44da304803e9841dc01"><gtr:id>d9a462504f3ef44da304803e9841dc01</gtr:id><gtr:otherNames>Day J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>564eaa052e7967.53228987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF50A3B1-C8A7-49C5-AD0B-B1D6140E53BA</gtr:id><gtr:title>A Model CNS Fungal Infection: Cryptococcal Meningitis</gtr:title><gtr:parentPublicationTitle>Current Clinical Microbiology Reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c4724e2a5c7d3379ef01fabff0b7f22"><gtr:id>6c4724e2a5c7d3379ef01fabff0b7f22</gtr:id><gtr:otherNames>Beardsley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>564eac915516c7.85126341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF7AA39F-6F4D-407E-9BCE-B94BE2F062A8</gtr:id><gtr:title>Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b28dd54456bcecf5b45c4f70889787b"><gtr:id>9b28dd54456bcecf5b45c4f70889787b</gtr:id><gtr:otherNames>Loyse A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_14098_28_23788479</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8F83E9B-C2BE-401A-B556-C1130E20BCD0</gtr:id><gtr:title>Viral aetiology of central nervous system infections in adults admitted to a tertiary referral hospital in southern Vietnam over 12 years.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/255afffa2b21d3e7057eeed107d015f8"><gtr:id>255afffa2b21d3e7057eeed107d015f8</gtr:id><gtr:otherNames>Tan le V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>544dc90a096201.71268851</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1696A0B-530A-4D15-B946-9073E33C2EE2</gtr:id><gtr:title>Clonality despite sex: the evolution of host-associated sexual neighborhoods in the pathogenic fungus Penicillium marneffei.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c5a6ca9653af9219ab454e15820baf0"><gtr:id>6c5a6ca9653af9219ab454e15820baf0</gtr:id><gtr:otherNames>Henk DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>RTeCTUX6VwE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60339344-2B8E-4791-9C64-176F14DC5545</gtr:id><gtr:title>Limitation of the Benefit of Amphotericin-Flucytosine Combination Therapy in Patients With Lower Conscious Level: An Ecological Fallacy?</gtr:title><gtr:parentPublicationTitle>Open forum infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0c1b39da8809fe4f563fda5119481a"><gtr:id>2d0c1b39da8809fe4f563fda5119481a</gtr:id><gtr:otherNames>Wolbers M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2328-8957</gtr:issn><gtr:outcomeId>564eaade59f408.42355390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEF63901-5ED6-431A-847A-9D7C9337B559</gtr:id><gtr:title>Relationship of susceptibility testing of Cryptococcus neoformans to survival and mycological clearance in HIV associated cryptococcal meningitis.</gtr:title><gtr:parentPublicationTitle>Mycoses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a81ba81d77ea4522025519116390463"><gtr:id>4a81ba81d77ea4522025519116390463</gtr:id><gtr:otherNames>JN Day</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>544dca6316e570.05234399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80FC90BE-68AA-4344-B67B-9A480F6ABC7B</gtr:id><gtr:title>Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ece84f61ae6c028ab6eb197573613266"><gtr:id>ece84f61ae6c028ab6eb197573613266</gtr:id><gtr:otherNames>Murray CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>544dcb6027f4c8.71238800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDBAD396-32EE-4C6B-8932-5267FC62628A</gtr:id><gtr:title>Second-Line HIV Therapy Outcomes and Determinants of Mortality at the Largest HIV Referral Center in Southern Vietnam.</gtr:title><gtr:parentPublicationTitle>Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e2fdca735ca5352dcce9ebbfa672877"><gtr:id>1e2fdca735ca5352dcce9ebbfa672877</gtr:id><gtr:otherNames>Thao VP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0025-7974</gtr:issn><gtr:outcomeId>564eab5adf73f2.26490634</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48FEABAF-9114-48B5-BD6A-CE7A530EE9A9</gtr:id><gtr:title>Combination Antifungal Therapy for Cryptococcal Meningitis</gtr:title><gtr:parentPublicationTitle>NEW ENGLAND JOURNAL OF MEDICINE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07453c4bf49315906daf594634db7d4f"><gtr:id>07453c4bf49315906daf594634db7d4f</gtr:id><gtr:otherNames>Loyse Angela</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>5a36094a040d83.64203374</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E908C6F-5297-467F-B251-6B79D0BE083D</gtr:id><gtr:title>AIDS-related mycoses: the way forward.</gtr:title><gtr:parentPublicationTitle>Trends in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9e7670819526636d49a136b653addc7"><gtr:id>e9e7670819526636d49a136b653addc7</gtr:id><gtr:otherNames>Brown GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0966-842X</gtr:issn><gtr:outcomeId>564eaa63245250.57598600</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7870AC1-F6C3-43DC-BA9B-B97F9841A479</gtr:id><gtr:title>Sertraline for HIV-associated cryptococcal meningitis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8eee7327fc045497226ac03290a147d4"><gtr:id>8eee7327fc045497226ac03290a147d4</gtr:id><gtr:otherNames>Veringa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>58a038edebbe56.23002602</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15854281-28A1-435A-ABD9-6F7FDEE2265C</gtr:id><gtr:title>Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03651961a46c5047f3fe6a41a37ce3b1"><gtr:id>03651961a46c5047f3fe6a41a37ce3b1</gtr:id><gtr:otherNames>Heemskerk AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>564eaddfd42354.09942301</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3155456E-3C09-48C9-A7E4-7A559B4C6CED</gtr:id><gtr:title>Clinical presentations, diagnosis, mortality and prognostic markers of tuberculous meningitis in Vietnamese children: a prospective descriptive study.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2aa9d06e83e433031161286b32e092c1"><gtr:id>2aa9d06e83e433031161286b32e092c1</gtr:id><gtr:otherNames>Bang ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>58a038ed9b8651.15882974</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABEA713D-867B-4267-95FB-0D52C3D7B3A2</gtr:id><gtr:title>Evaluation of GeneXpert MTB/RIF for diagnosis of tuberculous meningitis.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d0df72972df5765427845cb9e783c1a"><gtr:id>1d0df72972df5765427845cb9e783c1a</gtr:id><gtr:otherNames>Nhu NT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>544dc9f97d6649.47312385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B754BD96-E6C2-4C34-B55B-2C9650A51C01</gtr:id><gtr:title>Combination antifungal therapy for cryptococcal meningitis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f7aa2ed083c8bd45d89b327a099cdfa"><gtr:id>4f7aa2ed083c8bd45d89b327a099cdfa</gtr:id><gtr:otherNames>Day JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>b4Vsj29ntEo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD54D0B7-917F-4A54-8C25-0AEAF908D63F</gtr:id><gtr:title>Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ecac8939e47d735242b710466146e03"><gtr:id>6ecac8939e47d735242b710466146e03</gtr:id><gtr:otherNames>Kassebaum NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>544dcbfdba6565.27124898</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100684</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>